Top Markets
#1 MowCat MowCat +48.69%
#2 Bermuda Shorts Bermuda Shorts +30.68%
#3 Biconomy Biconomy +26.35%
#4 Velvet Velvet +23.94%
#5 Quack AI Quack AI +20.15%
#6 Derive Derive +16.90%
#7 DUSK Network DUSK Network +13.76%
#8 Zerebro Zerebro +13.35%
#9 Block Street Block Street +13.19%
#10 Perle Perle +12.91%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vivimed Labs Ltd. Vivimed Labs Ltd.

Vivimed Labs Ltd.

VIVIMEDLAB
Classifica tra le azioni #35079
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs... Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
Prezzo delle azioni
$0.05418616
Ultima sincronizzazione: 2026-08-14
Capitalizzazione di mercato
$4.49M
Variazione (1 giorno)
-1.01%
Variazione (1 anno)
-4.01%
Paese
IN
Scambia Vivimed Labs Ltd. (VIVIMEDLAB)

Categoria

Healthcare
Rapporto P/E per Vivimed Labs Ltd. (VIVIMEDLAB)
Rapporto P/E al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Vivimed Labs Ltd., il rapporto P/E attuale (TTM) è 0. Alla fine del 2026, il rapporto P/E era 0.
Storico del rapporto P/E per Vivimed Labs Ltd. da 2026 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
Non abbastanza dati per le date fornite.
Rapporto P/E per aziende simili o concorrenti
Azienda P/E Ratio Differenza del P/E Ratio Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.29 -
IN
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.